Details of the Drug

General Information of Drug (ID: DMQUSBT)

Drug Name
Daunorubicin
Synonyms
daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1], [2]
Kaposi sarcoma 2B57 Approved [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 527.5
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 24.8 mg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 47.57 mL/min/kg [7]
Elimination
40% of daunorubicin is excreted in the bile while 25% is excreted in an active form (daunorubicin or daunorubicinol) in the urine [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 18.5 +/- 4.9 hours [9]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.04727 micromolar/kg/day [10]
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [7]
Vd
The volume of distribution (Vd) of drug is 6.6 L [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0392 mg/mL [6]
Chemical Identifiers
Formula
C27H29NO10
IUPAC Name
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
InChI
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
InChIKey
STQGQHZAVUOBTE-VGBVRHCVSA-N
Cross-matching ID
PubChem CID
30323
ChEBI ID
CHEBI:41977
CAS Number
20830-81-3
DrugBank ID
DB00694
TTD ID
D01XWG
VARIDT ID
DR00284
INTEDE ID
DR0424

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA replication (DNA repli) TTABD5E NOUNIPROTAC Modulator [11]
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Intercalator [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 6 (ABCC6) DT582KR MRP6_HUMAN Substrate [13]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [15]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [16]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [17]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [17]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [17]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [18]
NADPH-dependent carbonyl reductase 1 (CBR1) DE9JFMC CBR1_HUMAN Substrate [19]
NADPH-dependent carbonyl reductase 3 (CBR3) DEIVKZ8 CBR3_HUMAN Substrate [20]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Daunorubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [103]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Midostaurin. Acute myeloid leukaemia [2A60] [104]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Idarubicin. Acute myeloid leukaemia [2A60] [104]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Arn-509. Acute myeloid leukaemia [2A60] [105]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [106]
Coadministration of a Drug Treating the Disease Different from Daunorubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [107]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Oliceridine. Acute pain [MG31] [104]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Rivastigmine. Alzheimer disease [8A20] [104]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Donepezil. Alzheimer disease [8A20] [104]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Daunorubicin and Metronidazole. Amoebiasis [1A36] [108]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ivabradine. Angina pectoris [BA40] [105]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Bepridil. Angina pectoris [BA40] [104]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Dronedarone. Angina pectoris [BA40] [104]
Nifedipine DMSVOZT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Nifedipine. Angina pectoris [BA40] [107]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Daunorubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [109]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Cilostazol. Arterial occlusive disease [BD40] [104]
Posaconazole DMUL5EW Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [107]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Levalbuterol. Asthma [CA23] [110]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Terbutaline. Asthma [CA23] [111]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Pirbuterol. Asthma [CA23] [111]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Salbutamol. Asthma [CA23] [110]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Roflumilast. Asthma [CA23] [105]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Formoterol. Asthma [CA23] [111]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [105]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Desipramine. Attention deficit hyperactivity disorder [6A05] [104]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ofloxacin. Bacterial infection [1A00-1C4Z] [112]
Clarithromycin DM4M1SG Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [107]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Daunorubicin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [104]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [112]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [112]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Norfloxacin. Bacterial infection [1A00-1C4Z] [112]
ABT-492 DMJFD2I Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [113]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Levofloxacin. Bacterial infection [1A00-1C4Z] [112]
Lomefloxacin DMVRH9C Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [113]
Telithromycin DMZ4P3A Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Telithromycin. Bacterial infection [1A00-1C4Z] [107]
Ag-221 DMS0ZBI Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [108]
Retigabine DMGNYIH Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Retigabine. Behcet disease [4A62] [107]
Erdafitinib DMI782S Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [114]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Loperamide. Bowel habit change [ME05] [115]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Eribulin. Breast cancer [2C60-2C6Y] [104]
Lapatinib DM3BH1Y Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [107]
HKI-272 DM6QOVN Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [107]
Tucatinib DMBESUA Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [107]
Alpelisib DMEXMYK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [107]
Atorvastatin DMF28YC Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Atorvastatin. Cardiovascular disease [BA00-BE2Z] [107]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [116]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [111]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [110]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [111]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [111]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [111]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Isoproterenol. Conduction disorder [BC63] [110]
Ulipristal DMBNI20 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [107]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Halothane. Corneal disease [9A76-9A78] [104]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Propofol. Corneal disease [9A76-9A78] [117]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sevoflurane. Corneal disease [9A76-9A78] [104]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Probucol. Coronary atherosclerosis [BA80] [104]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Clofazimine. Crohn disease [DD70] [118]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Daunorubicin and Mifepristone. Cushing syndrome [5A70] [104]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Daunorubicin and Pasireotide. Cushing syndrome [5A70] [104]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Osilodrostat. Cushing syndrome [5A70] [105]
Ivacaftor DMZC1HS Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [107]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sertraline. Depression [6A70-6A7Z] [104]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trimipramine. Depression [6A70-6A7Z] [104]
Nefazodone DM4ZS8M Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Nefazodone. Depression [6A70-6A7Z] [107]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Daunorubicin and Escitalopram. Depression [6A70-6A7Z] [104]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Clomipramine. Depression [6A70-6A7Z] [104]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Doxepin. Depression [6A70-6A7Z] [104]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Maprotiline. Depression [6A70-6A7Z] [104]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [104]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Deutetrabenazine. Dystonic disorder [8A02] [119]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ingrezza. Dystonic disorder [8A02] [120]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Solifenacin. Functional bladder disorder [GC50] [104]
Itraconazole DMCR1MV Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Itraconazole. Fungal infection [1F29-1F2F] [107]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pentamidine. Fungal infection [1F29-1F2F] [104]
Ketoconazole DMPZI3Q Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ketoconazole. Fungal infection [1F29-1F2F] [107]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [104]
Boceprevir DMBSHMF Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [107]
Telaprevir DMMRV29 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [107]
Daclatasvir DMSFK9V Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [107]
Delavirdine DM3NF5G Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Delavirdine. Human immunodeficiency virus disease [1C60-1C62] [107]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [121]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Daunorubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [122]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [104]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Daunorubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [123]
BMS-201038 DMQTAGO Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [107]
Felodipine DMOSW35 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Felodipine. Hypertension [BA00-BA04] [107]
Conivaptan DM1V329 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Conivaptan. Hypo-osmolality/hyponatraemia [5C72] [107]
Tolvaptan DMIWFRL Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [107]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [105]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Denosumab. Low bone mass disorder [FB83] [124]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Daunorubicin and Crizotinib. Lung cancer [2C25] [125]
Brigatinib DM7W94S Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [107]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Daunorubicin and Ceritinib. Lung cancer [2C25] [104]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Osimertinib. Lung cancer [2C25] [126]
Capmatinib DMYCXKL Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [107]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Daunorubicin and Selpercatinib. Lung cancer [2C25] [105]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Daunorubicin and Lumefantrine. Malaria [1F40-1F45] [108]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Daunorubicin and Halofantrine. Malaria [1F40-1F45] [127]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Daunorubicin and Hydroxychloroquine. Malaria [1F40-1F45] [128]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Primaquine. Malaria [1F40-1F45] [104]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [129]
Ponatinib DMYGJQO Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [107]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Vemurafenib. Melanoma [2C30] [104]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and LGX818. Melanoma [2C30] [130]
Lasmiditan DMXLVDT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [131]
Flibanserin DM70DTN Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Flibanserin. Mood disorder [6A60-6E23] [107]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Daunorubicin and Panobinostat. Multiple myeloma [2A83] [132]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Daunorubicin and Thalidomide. Multiple myeloma [2A83] [133]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Tecfidera. Multiple sclerosis [8A40] [134]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Daunorubicin and Siponimod. Multiple sclerosis [8A40] [108]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Fingolimod. Multiple sclerosis [8A40] [135]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Ocrelizumab. Multiple sclerosis [8A40] [136]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ozanimod. Multiple sclerosis [8A40] [105]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Romidepsin. Mycosis fungoides [2B01] [104]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [104]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [137]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [138]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Promethazine. Nausea/vomiting [MD90] [104]
Rolapitant DM8XP26 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [139]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Granisetron. Nausea/vomiting [MD90] [104]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Daunorubicin and Dolasetron. Nausea/vomiting [MD90] [104]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ondansetron. Nausea/vomiting [MD90] [104]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Entrectinib. Non-small cell lung cancer [2C25] [108]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [105]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lofexidine. Opioid use disorder [6C43] [104]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Rucaparib. Ovarian cancer [2C73] [104]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Buprenorphine. Pain [MG30-MG3Z] [104]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Triclabendazole. Parasitic worm infestation [1F90] [104]
Istradefylline DM20VSK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [107]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pimavanserin. Parkinsonism [8A00] [140]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Apomorphine. Parkinsonism [8A00] [104]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Famotidine. Peptic ulcer [DA61] [108]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Daunorubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [141]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Lefamulin. Pneumonia [CA40] [142]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ritodrine. Preterm labour/delivery [JB00] [111]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Degarelix. Prostate cancer [2C82] [105]
ABIRATERONE DM8V75C Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by ABIRATERONE. Prostate cancer [2C82] [107]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Enzalutamide. Prostate cancer [2C82] [105]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Relugolix. Prostate cancer [2C82] [105]
Darolutamide DMV7YFT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [143]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Bicalutamide. Prostate cancer [2C82] [105]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [144]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Canakinumab. Rheumatoid arthritis [FA20] [145]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Rilonacept. Rheumatoid arthritis [FA20] [145]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Daunorubicin and Golimumab. Rheumatoid arthritis [FA20] [146]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Daunorubicin and Leflunomide. Rheumatoid arthritis [FA20] [123]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Quetiapine. Schizophrenia [6A20] [104]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Daunorubicin and Mesoridazine. Schizophrenia [6A20] [104]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Aripiprazole. Schizophrenia [6A20] [108]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Daunorubicin and Iloperidone. Schizophrenia [6A20] [104]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Paliperidone. Schizophrenia [6A20] [104]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Perphenazine. Schizophrenia [6A20] [104]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trifluoperazine. Schizophrenia [6A20] [104]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Risperidone. Schizophrenia [6A20] [104]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Daunorubicin and Amisulpride. Schizophrenia [6A20] [147]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Asenapine. Schizophrenia [6A20] [104]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Pimozide. Schizophrenia [6A20] [105]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Daunorubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [148]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Vardenafil. Sexual dysfunction [HA00-HA01] [104]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Daunorubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [104]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [104]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [105]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [104]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pitolisant. Somnolence [MG42] [104]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [104]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Daunorubicin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [149]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lenvatinib. Thyroid cancer [2D10] [104]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Cabozantinib. Thyroid cancer [2D10] [105]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Papaverine. Tonus and reflex abnormality [MB47] [150]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Tizanidine. Tonus and reflex abnormality [MB47] [104]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Azathioprine. Transplant rejection [NE84] [108]
Tacrolimus DMZ7XNQ Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tacrolimus. Transplant rejection [NE84] [107]
Cinoxacin DM4EWNS Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [113]
Nalidixic acid DMRM0JV Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [113]
Elagolix DMB2C0E Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [107]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [151]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Procainamide. Ventricular tachyarrhythmia [BC71] [104]
Propafenone DMPIBJK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Propafenone. Ventricular tachyarrhythmia [BC71] [107]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [104]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Amiodarone. Ventricular tachyarrhythmia [BC71] [104]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Ganciclovir. Virus infection [1A24-1D9Z] [108]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Valganciclovir. Virus infection [1A24-1D9Z] [108]
⏷ Show the Full List of 178 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
5 Mayer LD, Tardi P, Louie AC: CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019.
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 FDA Approved Drug Products: Daunorubicin hydrochloride injection
9 Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
10 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
13 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
14 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
15 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
16 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
17 The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
18 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
19 Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
20 Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
21 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
22 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
23 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
24 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
25 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
26 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
27 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
28 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
29 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
30 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
31 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
32 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
33 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
34 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
35 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
36 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
37 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
38 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
39 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
40 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
41 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
42 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
43 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
44 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
45 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
46 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
47 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
48 Polycyclic aromatic hydrocarbon quinones and glutathione thioethers as substrates and inhibitors of the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase. J Biol Chem. 1987 Sep 15;262(26):12448-51.
49 In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
50 Metabolism of prostaglandins by the nonpregnant human uterus. J Clin Endocrinol Metab. 1983 Apr;56(4):678-85.
51 The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
52 Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
53 Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
54 Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
55 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
56 Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
57 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
58 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
59 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
60 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
61 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
62 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
63 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
64 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
65 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
66 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
67 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
68 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
69 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
70 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
71 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
72 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
73 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
74 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
75 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
76 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
77 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
78 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
79 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
80 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
81 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
82 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
83 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
84 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
85 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
86 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
87 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
88 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 3.A.1.208.10)
89 Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
90 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
91 Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.
92 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
93 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
94 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
95 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
96 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
97 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
98 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
99 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
100 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
101 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
102 Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
103 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
104 Canadian Pharmacists Association.
105 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
106 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
107 Multum Information Services, Inc. Expert Review Panel.
108 Cerner Multum, Inc. "Australian Product Information.".
109 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
110 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
111 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
112 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
113 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
114 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
115 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
116 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
117 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
118 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
119 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
120 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
121 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
122 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
123 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
124 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
125 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
126 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
127 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
128 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
129 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
130 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
131 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
132 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
133 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
134 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
135 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
136 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
137 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
138 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
139 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
140 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
141 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
142 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
143 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
144 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
145 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
146 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
147 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
148 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
149 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
150 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
151 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]